Take a look at how portable, long-read nanopore sequencing can be applied to the study of hepatitis B virus.
Recent technological advancements have allowed organoids to become a viable research tool for a wide range of development and disease models. Here, we look at some of the research that’s been done in infectious diseases and delve into what the future of organoids might look like.
Glenn Tillotson tells us about the interesting and rewarding opportunities young scientists could have in the pharmaceutical industry, highlighting how his own perceptions have changed over time.
Rabies elimination is achievable and cost-effective, but decades of research have failed to translate into multi-national efforts in the worst-affected areas. So why is the ancient rabies virus still terrorizing the lives of so many people across the globe?
Infectious diseases and population mobility are intimately linked from the perspectives of clinical practice to global health policy. Mobility bridges significant epidemiological differences in the classical determinants of health for all diseases. The new reality is that “surveillance, detection and response” activities in infectious diseases clinical care and public health are the responsibility all members of society.
Take a look at how advancements in genetic engineering has led to advances in vaccine manufacturing, with a divergence from live cell cultures to recombinant production in host cells.
Horizontal gene transfer plagues the control of multi-drug resistant infections, but how exactly are genes transferred and can we stop them? In a recent Cell paper, Rubio-Cosials and colleagues detail the biochemical events leading up to the transfer of transposons carrying antibiotic resistance genes.
TB and HIV are two intertwined infective challenges for global health and therefore they need to be addressed with an integrated approach.
Rapid detection and identification of pathogens is crucial to combat biothreat agents. Here, we take a look at some of the emerging technologies and how they could be used to diagnose disease for civilian biodefense.
We take a look at the key microbiome therapeutics currently in the clinical pipeline for recurrent C. difficile infections and their prospects for the treatment of this disease in the future.